This page shows the latest axitinib news and features for those working in and with pharma, biotech and healthcare.
has become an important first-line treatment option in combination with axitinib for patients with advanced renal cell carcinoma. ... Keytruda is currently approved in the US, Europe and Japan in combination with axitinib for the first-line treatment of
Both Opdivo combinations will compete with Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) plus Pfizer’s TKI Inlyta (axitinib), after the combination treatment received FDA approval in the same
drugs Ibrance (palbociclib) and Inlyta (axitinib).
Merck already has approval for another combination treatment, Keytruda plus Inlyta (axitinib), for the first-line treatment of advanced RCC.
However, it has been facing competition from Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) plus Pfizer’s TKI Inlyta (axitinib) after the combination treatment won US Food and Drug
Bavencio (avelumab), in combination with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), has been recommended as a first-line treatment for adult patients with advanced renal cell carcinoma (RCC) – the most
More from news
Approximately 5 fully matching, plus 39 partially matching documents found.
They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...